These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26941182)

  • 1. Molecular interactions of polo-like kinase 1 in human cancers.
    Weng Ng WT; Shin JS; Roberts TL; Wang B; Lee CS
    J Clin Pathol; 2016 Jul; 69(7):557-62. PubMed ID: 26941182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
    Lin YC; Sun SH; Wang FF
    Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
    Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
    Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
    Fischer M; Quaas M; Nickel A; Engeland K
    Oncotarget; 2015 Dec; 6(39):41402-17. PubMed ID: 26595675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of p21 with NF-YA suppresses the expression of Polo-like kinase 1 and prevents mitotic death in response to DNA damage.
    Lin YC; Chen YN; Lin KF; Wang FF; Chou TY; Chen MY
    Cell Death Dis; 2014 Jan; 5(1):e987. PubMed ID: 24407240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1).
    Kreis NN; Sommer K; Sanhaji M; Krämer A; Matthess Y; Kaufmann M; Strebhardt K; Yuan J
    Cell Cycle; 2009 Feb; 8(3):460-72. PubMed ID: 19177004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53-dependent repression of polo-like kinase-1 (PLK1).
    McKenzie L; King S; Marcar L; Nicol S; Dias SS; Schumm K; Robertson P; Bourdon JC; Perkins N; Fuller-Pace F; Meek DW
    Cell Cycle; 2010 Oct; 9(20):4200-12. PubMed ID: 20962589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXM1 and polo-like kinase 1 are co-ordinately overexpressed in patients with gastric adenocarcinomas.
    Dibb M; Han N; Choudhury J; Hayes S; Valentine H; West C; Sharrocks AD; Ang YS
    BMC Res Notes; 2015 Nov; 8():676. PubMed ID: 26576650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitric oxide down-regulates polo-like kinase 1 through a proximal promoter cell cycle gene homology region.
    Zhang J; Wang S; Kern S; Cui X; Danner RL
    J Biol Chem; 2007 Jan; 282(2):1003-9. PubMed ID: 17121839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
    Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
    Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 Suppresses E2F1-dependent PLK1 expression upon DNA damage by forming p53-E2F1-DNA complex.
    Zhou Z; Cao JX; Li SY; An GS; Ni JH; Jia HT
    Exp Cell Res; 2013 Dec; 319(20):3104-15. PubMed ID: 24076372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of Polo-like kinase 1 induces cellular senescence in human primary cells through a p53-dependent pathway.
    Kim HJ; Cho JH; Kim JR
    J Gerontol A Biol Sci Med Sci; 2013 Oct; 68(10):1145-56. PubMed ID: 23525475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
    Kreis NN; Louwen F; Zimmer B; Yuan J
    Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PLK1 and FoxM1 expressions positively correlate in papillary thyroid carcinoma and their combined inhibition results in synergistic anti-tumor effects.
    Poyil PK; Siraj AK; Padmaja D; Parvathareddy SK; Thangavel S; Alobaisi K; Diaz R; Begum R; Haqawi W; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
    Mol Oncol; 2024 Mar; 18(3):691-706. PubMed ID: 38361222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin Signaling Regulates the FoxM1/PLK1/CENP-A Pathway to Promote Adaptive Pancreatic β Cell Proliferation.
    Shirakawa J; Fernandez M; Takatani T; El Ouaamari A; Jungtrakoon P; Okawa ER; Zhang W; Yi P; Doria A; Kulkarni RN
    Cell Metab; 2017 Apr; 25(4):868-882.e5. PubMed ID: 28286049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The RNA helicase/transcriptional co-regulator, p68 (DDX5), stimulates expression of oncogenic protein kinase, Polo-like kinase-1 (PLK1), and is associated with elevated PLK1 levels in human breast cancers.
    Iyer RS; Nicol SM; Quinlan PR; Thompson AM; Meek DW; Fuller-Pace FV
    Cell Cycle; 2014; 13(9):1413-23. PubMed ID: 24626184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDC2 Is an Important Driver of Vascular Smooth Muscle Cell Proliferation via FOXM1 and PLK1 in Pulmonary Arterial Hypertension.
    Pal-Ghosh R; Xue D; Warburton R; Hill N; Polgar P; Wilson JL
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plk1, a negative regulator of p21?
    Liu X
    Cell Cycle; 2009 Feb; 8(3):336-7. PubMed ID: 19164953
    [No Abstract]   [Full Text] [Related]  

  • 19. Centrosomal protein 55 (Cep55) stability is negatively regulated by p53 protein through Polo-like kinase 1 (Plk1).
    Chang YC; Wu CH; Yen TC; Ouyang P
    J Biol Chem; 2012 Feb; 287(6):4376-85. PubMed ID: 22184120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Participation of PLK1 and FOXM1 in the hyperplastic proliferation of pulmonary artery smooth muscle cells in pulmonary arterial hypertension.
    Wilson JL; Wang L; Zhang Z; Hill NS; Polgar P
    PLoS One; 2019; 14(8):e0221728. PubMed ID: 31437238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.